An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety of Lenvatinib Monotherapy or Lenvatinib Combination Regimen or Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials
Phase of Trial: Phase II
Latest Information Update: 19 Aug 2019
Price : $35 *
At a glance
- Drugs Lenvatinib (Primary)
- Indications Lymphoma; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd; Eisai Inc
- 07 Jun 2019 Planned End Date changed from 1 Mar 2028 to 25 Sep 2020.
- 07 Jun 2019 Planned primary completion date changed from 1 Mar 2028 to 25 Sep 2020.
- 07 Jun 2019 Status changed from not yet recruiting to recruiting.